Latest Articles
GSK introduces Jemperli and Zejula in India to expand oncology portfolio - Express Pharma
GSK introduces Jemperli and Zejula in India to expand oncology portfolio Express Pharma
Published: Aug. 25, 2025, 11 a.m.
GSK forays into oncology in India with Jemperli and Zejula - Indian Pharma Post
GSK forays into oncology in India with Jemperli and Zejula Indian Pharma Post
Published: Aug. 25, 2025, 10:23 a.m.
GSK enters Indian oncology market with gynaecological cancer drugs - The New Indian Express
GSK enters Indian oncology market with gynaecological cancer drugs The New Indian Express
Published: Aug. 25, 2025, 8:44 a.m.
GSK enters into oncology segment; launches therapies for gynaecological cancers - newsdrum.in
GSK enters into oncology segment; launches therapies for gynaecological cancers newsdrum.in
Published: Aug. 25, 2025, 8 a.m.
A Cross-Sectional Study of Endometriosis Surgeries Across Obstetrics and Gynecology Subspecialties: Does Minimally Invasive Gynecologic Surgery (MIGS) Fellowship Training Make a Difference?
Objective The objective of this study was to compare the surgical approaches and postoperative outcomes of endometriosis surgeries performed by different obstetrics and gynecology (OBGYN) subspecialties: minimally invasive gynecologic surgery …
Published: Aug. 23, 2025, midnight
Does This Patient Really Need a Gyn Oncology Referral? - Cleveland Clinic
Does This Patient Really Need a Gyn Oncology Referral? Cleveland Clinic
Published: Aug. 19, 2025, 4:55 a.m.
Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight - The Malaysian Reserve
Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight The Malaysian Reserve
Published: Aug. 12, 2025, 10:20 p.m.
AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in - GlobeNewswire
AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in GlobeNewswire
Published: Aug. 6, 2025, 1:03 p.m.
First immunotherapy combination for endometrial cancer approved by NICE - Oncology Central
First immunotherapy combination for endometrial cancer approved by NICE Oncology Central
Published: Aug. 6, 2025, 11:18 a.m.
Selinexor Maintenance Offers Durable Benefit in Advanced Endometrial Cancer - Oncology Nursing News
Selinexor Maintenance Offers Durable Benefit in Advanced Endometrial Cancer Oncology Nursing News
Published: June 27, 2025, 6:10 p.m.
Link copied to clipboard!